Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A.
Azithromycin is an effective treatment for uncomplicated infections with Salmonella enterica serovar Typhi and serovar Paratyphi A (enteric fever), but there are no clinically validated MIC and disk zone size interpretative guidelines. We studied individual patient data from three randomized control...
| Հիմնական հեղինակներ: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Ձևաչափ: | Journal article |
| Լեզու: | English |
| Հրապարակվել է: |
American Society of Microbiology
2015
|
| _version_ | 1826278331290484736 |
|---|---|
| author | Parry, C Thieu, N Dolecek, C Karkey, A Gupta, R Turner, P Dance, D Maude, R Ha, V Tran, C Thi, P Be, b Phi, L Ngoc, R Ghose, A Dongol, S Campbell, J Thanh, D Thanh, T Moore, C Sona, S Gaind, R Deb, M Anh, H Van, S Tinh, H Day, N Dondorp, A Thwaites, G Faiz, M Phetsouvanh, R Newton, P Basnyat, B Farrar, J Baker, S |
| author_facet | Parry, C Thieu, N Dolecek, C Karkey, A Gupta, R Turner, P Dance, D Maude, R Ha, V Tran, C Thi, P Be, b Phi, L Ngoc, R Ghose, A Dongol, S Campbell, J Thanh, D Thanh, T Moore, C Sona, S Gaind, R Deb, M Anh, H Van, S Tinh, H Day, N Dondorp, A Thwaites, G Faiz, M Phetsouvanh, R Newton, P Basnyat, B Farrar, J Baker, S |
| author_sort | Parry, C |
| collection | OXFORD |
| description | Azithromycin is an effective treatment for uncomplicated infections with Salmonella enterica serovar Typhi and serovar Paratyphi A (enteric fever), but there are no clinically validated MIC and disk zone size interpretative guidelines. We studied individual patient data from three randomized controlled trials (RCTs) of antimicrobial treatment in enteric fever in Vietnam, with azithromycin used in one treatment arm, to determine the relationship between azithromycin treatment response and the azithromycin MIC of the infecting isolate. We additionally compared the azithromycin MIC and the disk susceptibility zone sizes of 1,640 S. Typhi and S. Paratyphi A clinical isolates collected from seven Asian countries. In the RCTs, 214 patients who were treated with azithromycin at a dose of 10 to 20 mg/ml for 5 to 7 days were analyzed. Treatment was successful in 195 of 214 (91%) patients, with no significant difference in response (cure rate, fever clearance time) with MICs ranging from 4 to 16 μg/ml. The proportion of Asian enteric fever isolates with an MIC of ≤ 16 μg/ml was 1,452/1,460 (99.5%; 95% confidence interval [CI], 98.9 to 99.7) for S. Typhi and 207/240 (86.3%; 95% CI, 81.2 to 90.3) (P < 0.001) for S. Paratyphi A. A zone size of ≥ 13 mm to a 5-μg azithromycin disk identified S. Typhi isolates with an MIC of ≤ 16 μg/ml with a sensitivity of 99.7%. An azithromycin MIC of ≤ 16 μg/ml or disk inhibition zone size of ≥ 13 mm enabled the detection of susceptible S. Typhi isolates that respond to azithromycin treatment. Further work is needed to define the response to treatment in S. Typhi isolates with an azithromycin MIC of >16 μg/ml and to determine MIC and disk breakpoints for S. Paratyphi A. |
| first_indexed | 2024-03-06T23:42:19Z |
| format | Journal article |
| id | oxford-uuid:6fbe72fb-0cd0-474b-84c9-868070083c65 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:42:19Z |
| publishDate | 2015 |
| publisher | American Society of Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:6fbe72fb-0cd0-474b-84c9-868070083c652022-03-26T19:32:44ZClinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6fbe72fb-0cd0-474b-84c9-868070083c65EnglishSymplectic Elements at OxfordAmerican Society of Microbiology2015Parry, CThieu, NDolecek, CKarkey, AGupta, RTurner, PDance, DMaude, RHa, VTran, CThi, PBe, bPhi, LNgoc, RGhose, ADongol, SCampbell, JThanh, DThanh, TMoore, CSona, SGaind, RDeb, MAnh, HVan, STinh, HDay, NDondorp, AThwaites, GFaiz, MPhetsouvanh, RNewton, PBasnyat, BFarrar, JBaker, SAzithromycin is an effective treatment for uncomplicated infections with Salmonella enterica serovar Typhi and serovar Paratyphi A (enteric fever), but there are no clinically validated MIC and disk zone size interpretative guidelines. We studied individual patient data from three randomized controlled trials (RCTs) of antimicrobial treatment in enteric fever in Vietnam, with azithromycin used in one treatment arm, to determine the relationship between azithromycin treatment response and the azithromycin MIC of the infecting isolate. We additionally compared the azithromycin MIC and the disk susceptibility zone sizes of 1,640 S. Typhi and S. Paratyphi A clinical isolates collected from seven Asian countries. In the RCTs, 214 patients who were treated with azithromycin at a dose of 10 to 20 mg/ml for 5 to 7 days were analyzed. Treatment was successful in 195 of 214 (91%) patients, with no significant difference in response (cure rate, fever clearance time) with MICs ranging from 4 to 16 μg/ml. The proportion of Asian enteric fever isolates with an MIC of ≤ 16 μg/ml was 1,452/1,460 (99.5%; 95% confidence interval [CI], 98.9 to 99.7) for S. Typhi and 207/240 (86.3%; 95% CI, 81.2 to 90.3) (P < 0.001) for S. Paratyphi A. A zone size of ≥ 13 mm to a 5-μg azithromycin disk identified S. Typhi isolates with an MIC of ≤ 16 μg/ml with a sensitivity of 99.7%. An azithromycin MIC of ≤ 16 μg/ml or disk inhibition zone size of ≥ 13 mm enabled the detection of susceptible S. Typhi isolates that respond to azithromycin treatment. Further work is needed to define the response to treatment in S. Typhi isolates with an azithromycin MIC of >16 μg/ml and to determine MIC and disk breakpoints for S. Paratyphi A. |
| spellingShingle | Parry, C Thieu, N Dolecek, C Karkey, A Gupta, R Turner, P Dance, D Maude, R Ha, V Tran, C Thi, P Be, b Phi, L Ngoc, R Ghose, A Dongol, S Campbell, J Thanh, D Thanh, T Moore, C Sona, S Gaind, R Deb, M Anh, H Van, S Tinh, H Day, N Dondorp, A Thwaites, G Faiz, M Phetsouvanh, R Newton, P Basnyat, B Farrar, J Baker, S Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. |
| title | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. |
| title_full | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. |
| title_fullStr | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. |
| title_full_unstemmed | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. |
| title_short | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. |
| title_sort | clinically and microbiologically derived azithromycin susceptibility breakpoints for salmonella enterica serovars typhi and paratyphi a |
| work_keys_str_mv | AT parryc clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT thieun clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT dolecekc clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT karkeya clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT guptar clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT turnerp clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT danced clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT mauder clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT hav clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT tranc clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT thip clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT beb clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT phil clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT ngocr clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT ghosea clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT dongols clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT campbellj clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT thanhd clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT thanht clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT moorec clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT sonas clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT gaindr clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT debm clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT anhh clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT vans clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT tinhh clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT dayn clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT dondorpa clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT thwaitesg clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT faizm clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT phetsouvanhr clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT newtonp clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT basnyatb clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT farrarj clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia AT bakers clinicallyandmicrobiologicallyderivedazithromycinsusceptibilitybreakpointsforsalmonellaentericaserovarstyphiandparatyphia |